MAPT and frontotemporal dementia: A subsequent multicenter GENFI cohort study confirmed the utility of CSF and plasma complement proteins as biomarkers for presymptomatic and symptomatic FTD patients, including carriers of GRN, C9orf72, or MAPT mutations (n = 224) [24].